Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference
PURCHASE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company...
PURCHASE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company...
Revolutionary inhaled nitric oxide technology set to reach broader healthcare systemsGARDEN CITY, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Beyond...
- Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure - Sales and marketing efforts to...
GAITHERSBURG, Md., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it entered into a...
—Potential best-in-class targeted treatment for Netherton syndrome is company’s first protein therapeutic to advance to the clinic— —Initial data from...
Sample More Than 150 Unique Firkin-Style Beers at Long Island’s Most Iconic Beer FestivalPATCHOGUE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE)...
Strategic head-to-head study of BR-AC vs. standard of care aims to demonstrate healing superiority potential to support increased payor coverage...
NIAID will be conducting and sponsoring clinical trials to accelerate and to streamline the rapid development of next-generation COVID-19 vaccinesABINGDON,...
MALVERN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
Two informational posters for ORIGIN Phase 3 and ORIGIN Extend trials of atacicept in IgAN accepted for presentation at Kidney...
PIONEER study expands the investigation of atacicept into a broad definition of IgA nephropathy and into multiple autoimmune glomerular diseases,...
Glioblastoma study achieves milestone with successful dose escalation, setting stage for Phase 2MILAN and NEW YORK, Oct. 02, 2024 (GLOBE...
SAN JUAN CAPISTRANO, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group...
ZUG, Switzerland, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mr. Char brings extensive experience in leading legal, compliance and corporate governance...
Mr. Char brings extensive experience in leading legal, compliance and corporate governance functions in successful biotech and medical device companiesThe...
Press release, Helsinki, 2 October 2024 at 9 AM (EEST) Nexstim Receives NBS System 5 Order from European Customer Nexstim...
EssilorLuxottica Completes Acquisition of Supreme® from VF Corporation Paris, France and Denver, Colorado (USA) (October 2, 2024 – 7am CEST)...
EssilorLuxottica Completes Acquisitionof a Majority Stake in Heidelberg Engineering Paris, France and Heidelberg, Germany (October 2, 2024 – 7am CEST) –...
Construction progress of world’s first PET enzymatic biorecycling plant in France: in line with production targets in 2026Commercial development:...
ORLANDO, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority...